Background: Automated insulin delivery aims to lower treatment burden and improve quality of life as well as glycemic outcomes.

Methods: This dual-centre, randomized, open-label, two-sequence cross-over study in automated insulin delivery naïve users, compared Medtronic Minimed® Advanced Hybrid Closed Loop (AHCL) to Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP+PLGM). At the end of each 4 week intervention impacts on quality of life were compared using age-appropriate scales: Diabetes Treatment Satisfaction Questionnaire status and change (DTSQs and DTSQc), Diabetes Technology Questionnaire (DTQ), Pittsburgh Sleep Quality Index (PSQI), World Health Organisation-Five Well-Being Index (WHO-5), Hypoglycemic Fear Survey (HFS-II) and Hypoglycemia Confidence Scale (HCS).

Results: 59/60 people completed the study (mean age 23.3±14.4yrs). Statistically significant differences favouring AHCL were demonstrated in several scales (data shown as mean±SE). Technology satisfaction favoured AHCL over PLGM as shown by a higher score in the DTSQs during AHCL (n=28) vs. SAP+PLGM (n=29) (30.9±0.7 vs. 27.9±0.7, p=0.004) and DTSQc AHCL (n=29) vs. SAP+PLGM (n=30) (11.7±0.9 vs. 9.2±0.8, p=0.032) in adults. Adolescents also showed a higher DTSQc score during AHCL (n=16) vs. SAP+PLGM (n=15) (14.8±0.7 vs. 12.1±0.8, p=0.024). The DTQ “change” score (n=59) favoured AHCL over SAP+ PLGM (3.5±0.0 vs. 3.3±0.0, p<0.001). Improved sleep quality was demonstrated by the lower PSQI in those aged over 16 years (n= 36) during AHCL vs. SAP+PLGM (4.8±0.3 vs. 5.7±0.3, p=0.048) with > 5 indicating poor quality sleep. No differences were found in the other scales.

Conclusion: The findings from this RCT suggest AHCL compared to SAP + PLGM mode has the potential to increase treatment satisfaction and improve subjective sleep quality in adolescents and adults with T1D.


O. Collyns: None. R. Meier: None. Z. Betts: None. D. Chan: None. C. Frampton: None. C.M. Frewen: None. B. Galland: None. N. Hewapathirana: Other Relationship; Self; Sanofi. S. Jones: None. N. Kurtz: Employee; Self; Medtronic. J. Shin: Employee; Self; Medtronic. R. Vigersky: Employee; Self; Medtronic. B.J. Wheeler: Research Support; Self; Medtronic. M. de Bock: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at